Skin permeation and ex vivo skin metabolism of O-acyl haloperidol ester prodrugs

International Journal of Pharmaceutics

Volumn 367, Issue 1-2, 2009, Pages 44-50

  Morris, Andrew P ^a   Brain, Keith R ^a   Heard, Charles M ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cetrimide; Ester; Haloperidol; Prodrug; Receptor phase; Skin; Transdermal drug delivery

Indexed keywords

ESTERASE; HALOPERIDOL; HALOPERIDOL BUTANOATE; HALOPERIDOL DECANOATE; HALOPERIDOL ETHANOATE; HALOPERIDOL OCTANOATE; HALOPERIDOL PROPANOATE; LIVER EXTRACT; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG PENETRATION; DRUG STABILITY; HYDROLYSIS; MALE; NONHUMAN; PRIORITY JOURNAL; SKIN PERMEABILITY;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIPSYCHOTIC AGENTS; BIOLOGICAL TRANSPORT; DRUG STABILITY; ESTERS; FEMALE; GUINEA PIGS; HALOPERIDOL; HUMANS; HYDROLYSIS; LIVER; MALE; MOLECULAR STRUCTURE; PERMEABILITY; PRODRUGS; SKIN; SKIN ABSORPTION; SOLUBILITY; TISSUE EXTRACTS;

EID: 58249102957     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.09.013     Document Type: Article

References (45)

1. Almirall M., Montana J., Escribano E., Obach R., and Berrozpe J.D. Effect of d-limonene, alpha-pinene and cineole on in vitro transdermal human skin penetration of chlorpromazine and haloperidol. Arzneim-Forsch/Drug. Res. 46 (1996) 676-680
2. Birchall J.C., Marichal C., Campbell L., Alwan A., Hadgraft J., and Gumbleton M. Gene expression in an intact ex-vivo skin tissue model following percutaneous delivery of cationic liposome-plasmid DNA complexes. Int. J. Pharm. 197 (2000) 233-238
3. Bond J.R., and Barry B.W. Limitations of hairless mouse skin as a model for in vitro permeation studies through human skin: hydration damage. J. Invest. Dermatol. 90 (1986) 486-489
4. Bond J.R., and Barry B.W. Damaging effect of acetone on the permeability barrier of hairless mouse skin compared with that of human skin. Int. J. Pharm. 41 (1988) 91-93
5. Bonina F.P., Puglia C., Barbuzzia T., de Caprariis P., Palagiano F., Rimoli M.G., and Saija A. In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur. J. Pharm. Sci. 14 (2001) 123-134
6. British National Formulary (BNF), 2008. Number 55, British Medical Association/Royal Pharmaceutical Society of Great Britain, London, UK.
7. Cheung Y.W., Li Wan Po A., and Irwin W.J. Cutaneous biotransformation as a parameter in the modulation of the activity of topical corticosteroids. Int. J. Pharm. 26 (1985) 175-189
8. Corrigan P.W., Liberman R.P., and Engel J.D. From noncompliance to collaboration in the treatment of schizophrenia. Hosp. Community Psychiatr. 41 (1990) 1203-1211
9. Elgorashi A.S., Heard C.M., Niazy E.M., Noureldin O.H., and Pugh W.J. Transdermal delivery enhancement of haloperidol from gel formulations by 1,8-cineole. J. Pharm. Pharmacol. 60 (2008) 689-692
10. Eyles D.W., McGrath J.J., Stedman T.J., and Pond S.M. Chirality of reduced haloperidol in humans. Eur. Neuropsychopharmacol. 8 (1998) 127-129
11. Haberland A., Schreiber S., Santos Maia C., Rübbelke M.K., Schaller M., Korting H.C., Kleuser B., Schimke I., and Schäfer-Korting M. The impact of skin viability on drug metabolism and permeation-BSA toxicity on primary keratinocytes. Toxicol. In Vitro 20 (2006) 347-354
12. Hamann G.L., Egan T.M., Wells B.G., and Grimmig J.E. Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/ml. J. Clin. Psychiatry 51 (1990) 502-504
13. Heard C.M., and Screen C. Probing the permeation enhancement of mefenamic acid by ethanol across full thickness skin, heat-separated epidermal membrane and heat-separated dermal membrane. Int. J. Pharm. 349 (2008) 323-325
14. Heard C.M., Kung D., and Thomas C.P. Skin penetration enhancement of mefenamic acid by ethanol and 1,8-cineole can be explained by the pull effect. Int. J. Pharm. 321 (2006) 167-170
15. Henke E., Pleiss J., and Bornscheuer U.T. Activity of lipases and esterases towards tertiary alcohols: insights into structure-function relationships. Angew. Chem. Int. Ed. Engl. 41 (2002) 3211-3213
16. Hewitt P.G., Perkins J., and Hotchkiss S.A.M. Metabolism of fluroxypyr, Fluroxypyr methyl ester, and the herbicide Fluroxypyr methylheptyl ester. I. During percutaneous absorption through fresh rat and human skin in vitro drug metabolism and disposition. Drug Metab. Dispos. 28 (2000) 748-754
17. Holley F.O., Magliozzi J.R., Stanski D.R., Lombrozo L., and Hollister L.E. Haloperidol kinetics after oral and intravenous doses. Clin. Pharmacol. Ther. 33 (1983) 477-484
18. Hugo W.B., and Russell A.D. Pharmaceutical Microbiology. 5th ed. (1992), Blackwell Scientific Publications, Oxford
19. Lim P.F.C., Liu X.Y., Kang L., Ho P.C.L., Chan Y.W., and Chan S.Y. Limonene GP1/PG organogel as a vehicle in transdermal delivery of haloperidol. Int. J. Pharm. 311 (2006) 157-164
20. Martindale. The Complete Drug Reference. 34th ed. (2005), The Pharmaceutical Press, London
21. Montagna W. Histology and cytochemistry of human skin. IX. The distribution of non-specific esterases. J. Biophys. Biochem. Cytol. 1 (1955) 13-16
22. Morris A.P., Brain K.R., and Heard C.M. Synthesis of haloperidol prodrugs and their hydrolysis by porcine liver esterase. Drug Metab. Lett. 2 4 (2008) 275-279
23. Ng K.M.E., Chu I., Bronaugh R.L., Franklin C.A., and Somers D.A. Percutaneous absorption and metabolism of pyrene, benzo[α]pyrene, and di(2-ethylhexyl)phthalate: comparison of in vitro and in vivo results in the hairless guinea pig. Toxicol. Appl. Pharmacol. 115 (1992) 216-223
24. National Institute for Clinical Excellence (NICE), 2002. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal no. 43, London.
25. Oh S.Y., Fujii M., Takeda Y., Yoda K., Utoguchi N., Matsumoto M., and Watanabe Y. The effect of ethanol on the simultaneous transport and metabolism of methyl p-hydroxybenzoate in excised skin of Yucatan micropig. Int. J. Pharm. 236 (2002) 35-42
26. Ostacolo C., Marra F., Laneri S., Sacchi A., Nicoli S., Padula C., and Santi P. Alpha-tocopherol pro-vitamins: synthesis, hydrolysis and accumulation in rabbit ear skin. J. Control. Rel. 99 (2004) 403-413
27. Poon H., Elliot V., Bateman D.N., and Waring W.S. Impact of legislative changes on patterns of antipsychotic prescribing and self-poisoning in Scotland: 2000-06. J. Toxicol. Sci. 32 (2007) 1-7
28. Potts R.O., and Guy R.H. Predicting skin permeability. Pharm. Res. 9 (1992) 663-669
29. Roberts W.J., and Sloan K.B. Prediction of transdermal flux of prodrugs of 5-fluorouracil, theophylline, and 6-mercaptopurine with a series/parallel model. J. Pharm. Sci. 89 (2000) 1415-1431
30. Roy S.D., and Flynn G.L. Transdermal delivery of narcotic analgesics: pH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanil. Pharm. Res. 7 (1990) 842-847
31. Sartorelli P., Andersen H.R., Angerer J., Corish J., Drexler H., Göen T., Griffin P., Hotchkiss S.A.M., Larese F., Montomoli L., Perkins J., Schmelz M., van de Sandt J., and Williams F. Percutaneous penetration studies for risk assessment. Environ. Toxicol. Pharmacol. 8 (2000) 133-152
32. Scheuplein R.J., Blank I.H., Brauner G.J., and MacFarlane D.J. Percutaneous absorption of steroids. J. Invest. Dermat. 52 (1969) 63-70
33. Seville P., Simons C., Taylor G., and Dickinson P. Prodrug to probe solution HFA pMDI formulation and pulmonary esterase activity. Int. J. Pharm. 195 (2000) 13-16
34. Sloan K.B., Koch S.A.M., and Siver K.G. Mannich base derivatives of theophylline and 5-fluorouracil: synthesis, properties and topical delivery characteristics. Int. J. Pharm. 21 (1984) 251-264
35. Sloan K.B., Wasdo S., Ezike-Mkparu U., Murray T., Nickels D., Singh S., Shanks T., Tovar J., Ulmer K., and Waranis R. Topical delivery of 5-fluorouracil and 6-mercaptopurine by their alkylcarbonyloxymethyl prodrugs from water: vehicle effects on design of prodrugs. Pharm. Res. 20 (2003) 639-645
36. Stoddart, G., 2002. Optimisation of solubility parameter in design of naproxen prodrugs for transdermal delivery. Ph.D. Thesis, University of Wales, College of Cardiff, UK.
37. Thomas C.P., and Heard C.M. Probing the skin permeation of fish oil/EPA and ketoprofen. 2. Comparative depth profiling and metabolism of eicosapentaenoic acid. Eur. J. Pharm. Biopharm. 67 (2007) 156-165
38. Thomas C.P., Davison Z., and Heard C.M. Probing the skin permeation of fish oil/EPA and ketoprofen. 3. Influence of fish oil/ketoprofen on epidermal COX-2 and LOX. Prostaglandins Leukot. Essent. Fatty Acids 76 (2007) 357-362
39. Vaddi H.K., Wang L.Z., Ho P.C., and Chan S.Y. Effect of some enhancers on the permeation of haloperidol through rat skin in vitro. Int. J. Pharm. 212 (2001) 247-255
40. Vaddi H.K., Ho P.C., Chan Y.W., and Chan S.Y. Terpenes in ethanol: haloperidol permeation and partition through human skin and stratum corneum changes. J. Control. Release 81 (2002) 121-133
41. Valiveti S., Paudel K.S., Hammell D.C., Hamad M.O., Chen J., Crooks P.A., and Stinchcomb A.L. In vitro/in vivo correlation of transdermal naltrexone prodrugs in hairless guinea pigs. Pharm. Res. 22 (2005) 981-989
42. Waranis R.P., and Sloan K.B. Effects of vehicles and prodrug properties and their interactions on the delivery of 6-mercaptopurine through skin: bisacyloxymethyl-6-mercaptopurine prodrugs. J. Pharm. Sci. 76 (1987) 587-595
43. 6-acyloxymethyl-6-mercaptopurine prodrugs. J. Pharm. Sci. 77 (1988) 210-215
44. Wester R.C., Christoffel J., Hartway T., Poblete N., Maibach H., and Forsell J. Human cadaver skin viability for in vitro percutaneous absorption: storage and detrimental effects of heat-separation and freezing. Pharm. Res. 15 (1998) 82-84
45. Williams A.C. Transdermal and Topical Drug Delivery (2003), Pharmaceutical Press, London